| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/20/2001 | WO2001068144A2 Biodegradable immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068142A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 09/20/2001 | WO2001068139A1 Formulation solubilizing water-insoluble agents and preparation method thereof |
| 09/20/2001 | WO2001068135A2 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 09/20/2001 | WO2001068105A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 09/20/2001 | WO2001068098A2 Cephalotaxine alkaloid combination compositions and uses thereof |
| 09/20/2001 | WO2001068093A1 Use of glucosylceramide synthesis inhibitors in brain cancertherapy |
| 09/20/2001 | WO2001068089A1 Condensation derivatives of thiocolchicine and baccatin as antitumor agents |
| 09/20/2001 | WO2001068081A1 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd) |
| 09/20/2001 | WO2001068076A2 D-enantiomer of dfmo and methods of use thereof for treating cancer |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068071A2 Use of natural chrysanthone compounds having antiangiogenic activity |
| 09/20/2001 | WO2001068070A2 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis |
| 09/20/2001 | WO2001068068A2 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | WO2001068066A2 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068034A2 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001034591A3 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/20/2001 | WO2001030366A3 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases |
| 09/20/2001 | WO2001019850A3 Nrage nucleic acids and polypeptides and uses thereof |
| 09/20/2001 | WO2001019819A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 09/20/2001 | WO2001018051A3 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 09/20/2001 | WO2001018025A3 17alpha propynyl 11-aryl steroids |
| 09/20/2001 | WO2001016603A3 Analysis and treatment of body weight and eating disorders |
| 09/20/2001 | WO2001016317A3 Polycyclic aromatic hydrocarbon induced molecules |
| 09/20/2001 | WO2001016165A3 Apoptin-associating protein |
| 09/20/2001 | WO2001015675A3 Use of docetaxel for treating hepatocellular carcinoma |
| 09/20/2001 | WO2001014424A3 Human ctla-4 antibodies and their uses |
| 09/20/2001 | WO2001010427A3 Use of anti-muscarinic agents for treating skin disorders |
| 09/20/2001 | WO2001002540A9 Adenoviral vectors for treating disease |
| 09/20/2001 | WO2000047583A9 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 09/20/2001 | WO2000044774A9 Inhibition of stat3 signal transduction for human cancer therapy |
| 09/20/2001 | WO2000027378A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | US20010023292 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 09/20/2001 | US20010023291 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| 09/20/2001 | US20010023260 Method for preventing and treating peripheral neuropathy by administering selegiline |
| 09/20/2001 | US20010023250 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 09/20/2001 | US20010023242 Polypeptide from snake venom |
| 09/20/2001 | US20010023061 Assaying the effect of test tumor cell modulation |
| 09/20/2001 | US20010022979 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/20/2001 | US20010022976 Controlling lymphocyte activation, tumor necrosis factor |
| 09/20/2001 | US20010022970 Halogenated xanthan compound |
| 09/20/2001 | EP1143960A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | DE10010165A1 Composition for tumor treatment, comprises tumor antigen and recall antigen that stimulates attack by T cells, overcoming tolerance to the tumor |
| 09/20/2001 | DE10009030A1 Hybrid cell, useful as therapeutic vaccine against cancer and viral, bacterial and protozoal infections, comprises allogeneic dendritic cells fused to autologous non-dendritic cells |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403420A1 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403149A1 2-phenylpyran-4-one derivatives |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2403063A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 09/20/2001 | CA2403017A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | CA2402940A1 G-protein coupled receptors |
| 09/20/2001 | CA2402908A1 Assay for agents that induce chemokinesis |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402721A1 Derivatives of breast cancer antigen her-2 for therapeutical use |
| 09/20/2001 | CA2402710A1 Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402413A1 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | CA2402327A1 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | CA2402248A1 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | CA2402122A1 D-enantiomer of dfmo and methods of use therefor |
| 09/20/2001 | CA2402086A1 Self antigen vaccines for treating b cell lymphomas and other cancers |
| 09/20/2001 | CA2402041A1 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | CA2401873A1 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | CA2401267A1 Use of natural compounds having antiangiogenic activity |
| 09/20/2001 | CA2401252A1 Human and humanized fap-alpha-specific antibodies |
| 09/20/2001 | CA2400370A1 Nucleoside compounds and uses thereof |
| 09/20/2001 | CA2400238A1 Human nim1 kinase |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/20/2001 | CA2400043A1 Antiviral prodrugs |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1134286A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133992A1 Novel pharmacological activities of curcuma longa extracts |
| 09/19/2001 | EP1133990A1 Anti-tumor composition consisting of a fraction of gravid uterus or mammalian placenta |
| 09/19/2001 | EP1133988A1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/19/2001 | EP1133575A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 09/19/2001 | EP1133557A2 Growth factor modulators |
| 09/19/2001 | EP1133522A1 Antagonistic analogs of gh-rh inhibiting igf-i and -ii |
| 09/19/2001 | EP1133519A2 Functional antagonists of hedgehog activity |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133516A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 09/19/2001 | EP1133512A2 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133510A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133509A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133508A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133507A2 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133506A2 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133498A2 Amino-and mercurio-substituted 4', 5'-dihydropsoralens and therapeutical uses thereof |
| 09/19/2001 | EP1133491A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133486A2 Nonsteroidal antiinflammatories |
| 09/19/2001 | EP1133481A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133480A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |